(NASDAQ: ALLR) Allarity Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 56.52%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 101.52%.
Allarity Therapeutics's earnings in 2025 is -$24,657,000.On average, 3 Wall Street analysts forecast ALLR's earnings for 2025 to be -$12,675,224, with the lowest ALLR earnings forecast at -$12,178,157, and the highest ALLR earnings forecast at -$13,048,025. On average, 3 Wall Street analysts forecast ALLR's earnings for 2026 to be -$13,569,946, with the lowest ALLR earnings forecast at -$13,037,791, and the highest ALLR earnings forecast at -$13,969,062.
In 2027, ALLR is forecast to generate -$375,783,124 in earnings, with the lowest earnings forecast at -$361,046,531 and the highest earnings forecast at -$386,835,569.